A Single Dose of Novel PSMA-Targeting Radiopharmaceutical Agent [177Lu]Ludotadipep for Patients with Metastatic Castration-Resistant Prostate Cancer: Phase I Clinical Trial

被引:9
|
作者
Shin, Dongho [1 ]
Ha, Seunggyun [2 ]
Hyun, O. Joo [2 ]
Rhew, Seung Ah [1 ]
Yoon, Chang Eil [1 ]
Kwon, Hyeok Jae [1 ]
Moon, Hyong Woo [1 ]
Park, Yong Hyun [1 ]
Park, Sonya Youngju [2 ]
Park, Chansoo [3 ]
Chi, Dae Yoon [3 ]
Yoo, Ie Ryung [2 ]
Lee, Ji Youl [1 ]
机构
[1] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Urol, Seoul 06591, South Korea
[2] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Nucl Med, Seoul 06591, South Korea
[3] FutureChem Co Ltd, Res Inst Labeling, Seoul 04793, South Korea
基金
新加坡国家研究基金会;
关键词
metastatic castration-resistant prostate cancer; lutetium-177; PSMA; radiopharmaceutical therapy; RADIONUCLIDE THERAPY;
D O I
10.3390/cancers14246225
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Prostate specific membrane antigen (PSMA) is a transmembrane protein that is highly expressed in prostate cancer cells. For patients with metastatic castration-resistant prostate cancer (mCRPC) who do not respond to conventional treatment, PSMA targeting radiopharmaceutical therapy (RPT) has recently been in the spotlight. [Lu-177]Ludotadipep is a novel PSMA-targeting therapeutic agent designed with an albumin motif in order to increase the circulation time and uptake in the tumors. The safety and efficacy of [Lu-177]Ludotadipep were evaluated through a phase I trial. [Lu-177]Ludotadipep, which enables targeted delivery of beta-particle radiation to prostate tumor cells, had been suggested as a promising therapeutic option for mCRPC. From November 2020 to March 2022, a total of 30 patients were enrolled for single dose of [Lu-177]Ludotadipep RPT, 6 subjects in each of the 5 different activity groups of 1.9 GBq, 2.8 GBq, 3.7 GBq, 4.6 GBq, and 5.6 GBq. [Lu-177]Ludotadipep was administered via venous injection, and patients were hospitalized for three days to monitor for any adverse effects. Serum PSA levels were followed up at weeks 1, 2, 3, 4, 6, 8, and 12, and PSMA PET/CT with [F-18]Florastamin was obtained at baseline and again at weeks 4 and 8. The subjects required positive PSMA PET/CT prior to [Lu-177]Ludotadipep administration. Among the 29 subjects who received [Lu-177]Ludotadipep, 36 treatment emergent adverse events (TEAEs) occurred in 17 subjects (58.6%) and 4 adverse drug reactions (ADRs) in 3 subjects (10.3%). Of the total 24 subjects who had full 12-week follow-up data, 16 (66.7%) showed decrease in PSA of any magnitude, and 9 (37.5%) showed a decrease in PSA by 50% or greater. A total of 5 of the 24 patients (20.8%) showed disease progression (PSA increase of 25% or higher from the baseline) at the 12th week following single dose of [Lu-177]Ludotadipep. These data thus far suggest that [Lu-177]Ludotadipep could be a promising RPT agent with low toxicity in mCRPC patients who have not been responsive to conventional treatments.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer
    Mader, Nicolai
    Ngoc, Christina Nguyen
    Kirkgoeze, Bilge
    Baumgarten, Justus
    Groener, Daniel
    Klimek, Konrad
    Happel, Christian
    Tselis, Nikolaos
    Chun, Felix K. H.
    Gruenwald, Frank
    Sabet, Amir
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (06) : 1811 - 1821
  • [42] Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer
    Nicolai Mader
    Christina Nguyen Ngoc
    Bilge Kirkgöze
    Justus Baumgarten
    Daniel Groener
    Konrad Klimek
    Christian Happel
    Nikolaos Tselis
    Felix K. H. Chun
    Frank Grünwald
    Amir Sabet
    European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50 : 1811 - 1821
  • [43] Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy
    Ahmadzadehfar, Hojjat
    Schlolaut, Stephan
    Fimmers, Rolf
    Yordanova, Anna
    Hirzebruch, Stefan
    Schlenkhoff, Carl
    Gaertner, Florian C.
    Awang, Zool Hilmi
    Hauser, Stefan
    Essler, Markus
    ONCOTARGET, 2017, 8 (61) : 103108 - 103116
  • [44] Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial
    Armstrong, Andrew J.
    Sartor, Oliver
    de Bono, Johann
    Chi, Kim
    Fizazi, Karim
    Krause, Bernd J.
    Herrmann, Ken
    Rahbar, Kambiz
    Tagawa, Scott T.
    Saad, Fred
    Beer, Tomasz M.
    Wu, Jiwen
    Mirante, Osvaldo
    Morris, Michael J.
    EUROPEAN UROLOGY, 2024, 86 (06) : 552 - 562
  • [45] TheraP: A randomized phase II trial of [177Lu]-PSMA-617 theranostic versus cabazitaxel in progressive metastatic castration-resistant prostate cancer
    Hofman, Michael
    Emmett, Louise
    Violet, John A.
    Lawrence, Nicola Jane
    Williams, Scott
    Stockler, Martin R.
    Francis, Roslyn J.
    Iravani, Amir
    Zhang, Alison Yan
    Martin, Andrew James
    Azad, Arun
    Yip, Sonia
    Langford, Ailsa
    McJannett, Margaret Mary
    Davis, Ian D.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [46] ECONOMIC ANALYSIS OF 177LU-PSMA-I&T IN AUSTRALIAN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Ayati, Nayyereh
    INTERNAL MEDICINE JOURNAL, 2023, 53 : 31 - 31
  • [47] Evaluation of Nephrotoxicity of Extended Lu177-PSMA in Patients with Metastatic Castration-Resistant Prostate Cancer
    Topal, E.
    Kovan, B.
    Simsek, D. Has
    Civan, C.
    Sanli, M.
    Basaran, M.
    Sanli, Y.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S151 - S152
  • [49] Phase 3 Study of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer (VISION)
    Krause, B.
    de Bono, J.
    Chi, K. N.
    Fizazi, K.
    Herrmann, K.
    Rahbar, K.
    Tagawa, S. T.
    Nordquist, L. T.
    Vaishampayan, N.
    El-Haddad, G.
    Park, C. H.
    Beer, T. M.
    Perez-Contreras, W. J.
    DeSilvio, M.
    Kpamegan, E.
    Gericke, G.
    Messmann, R. A.
    Morris, M. J.
    Sartor, O.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S63 - S63
  • [50] [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
    Hofman, Michael S.
    Violet, John
    Hicks, Rodney J.
    Ferdinandus, Justin
    Thang, Sue Ping
    Akhurst, Tim
    Iravani, Amir
    Kong, Grace
    Kumar, Aravind Ravi
    Murphy, Declan G.
    Eu, Peter
    Jackson, Price
    Scalzo, Mark
    Williams, Scott G.
    Sandhu, Shahneen
    LANCET ONCOLOGY, 2018, 19 (06): : 825 - 833